News Nation Logo


Sun Pharmaceutical to buy Novartis' oncology product Odomzo for USD 175 million

Drug Major, Sun Pharmaceutical On Thursday Said It Plans To Acquire Branded Oncology Product Odomzo From Novartis For An Upfront Payment Of USD 175 Million.

News Nation Bureau | Edited By : Gautam Lalotra | Updated on: 22 Dec 2016, 11:22:58 AM
Sun Pharmaceuticals - File Photo

New Delhi:

Drug major, Sun Pharmaceutical on Thursday said it plans to acquire branded oncology product Odomzo from Novartis for an upfront payment of USD 175 million. 

The company, in its regulatory filing to stock exchanges, said the agreement has been signed between the subsidiaries of Sun Pharma and Novartis to buy Odomzo for an upfront payment of $ 175 million and additional milestone payments. 

Odomzo is used for treatment of adult patients with labcc that has recurred following surgery or radiation therapy. 

For all the Latest Business News, Companies & Commodities News, Download News Nation Android and iOS Mobile Apps.

First Published : 22 Dec 2016, 11:15:00 AM